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Hepcidin is upregulated by inﬂammation and iron. Inherited (HFE genotype) and treatment-related factors (blood units (BU),
Iron overload) aﬀecting hepcidin (measured by C-ELISA) were studied in 42 consecutive patients with AML prior to and after
allogeneic hematopoietic cell transplantation (HCT). Results. Elevated serum ferritin pre- and post-HCT was present in all
patients. Median hepcidin pre- and post-HCT of 358 and 398ng/mL, respectively, were elevated compared to controls (median
52ng/mL) (P<. 0001). Liver and renal function, prior chemotherapies, and conditioning had no impact on hepcidin. Despite
higher total BU after HCT compared to pretransplantation (P<. 0005), pre- and posttransplant ferritin and hepcidin were
similar. BU inﬂuenced ferritin (P = .001) and hepcidin (P = .001). No correlation of pre- or posttransplant hepcidin with
pretransplant ferritin was found. HFE genotype did not inﬂuence hepcidin. Conclusions. Hepcidin is elevated in AML patients
pre- and post-HCT due to transfusionaliron-loading suggesting that hepcidin synthesis remains intact despite chemotherapy and
HCT.
1.Introduction
Hepcidin,a25-amino acidantimicrobialpeptidesynthesized
intheliver,isthecentraliron-regulatoryhormonethatmedi-
ates the homeostasis of extracellular iron concentrations [1,
2].Studieshaveconﬁrmeditsroleasthenegativeregulatorof
iron absorption, recycling, and release from stores. Hepcidin
regulates iron export into plasma from tissues involved in
iron storage or transport such as duodenal enterocytes,
hepatocytes, macrophages, and the syncytial trophoblasts
of the placenta [3]. Hepcidin binds to the iron exporter
ferroportin and induces its internalization and degradation.
Systemic iron requirements and infectious as well as inﬂam-
matory stimuli modulate hepcidin expression [4, 5]. Its
transcriptionisupregulatedbycytokinessuchasinterleukin-
6 and interleukin-1 as well as by iron and is downregulated
by iron deﬁciency, ineﬀective erythropoiesis, and hypoxia
[4, 6]. Because of its sensitivity to inﬂammatory stimuli
and its eﬀect on iron export from various tissues, hepcidin
plays an essential role for iron disorders such as anemia
of inﬂammation [7]. Hepcidin expression is also associated
with transfusional iron overload in β-thalassemia and other
iron-loading anemias [8].2 Advances in Hematology
Additionally, evidence indicatesthat the hemochromato-
sis gene HFE might be required for the synthesis of hepcidin.
Recent studies with animal models of hemochromatosis sug-
gest an important role of HFE protein as an iron sensor and
upstream regulator of hepcidin in hepatocytes. Hepatocyte
HFE is necessary for signaling to hepcidin, presumably as a
constituent of a larger iron-sensing complex [9–12].
Ironoverload,mainlyduetomultiplebloodtransfusions,
isa commoncomplicationinrecipientsofhematopoieticcell
transplantation (HCT) [13]. Iron overload increases the
risk of infections, veno-occlusive disease, and hepatic dys-
function after HCT. An increase of pretransplant serum
ferritin levels, which usually reﬂects body iron stores, has
been shown to lower disease-free survival following HCT
and might increase the risk of graft-versus-host disease
(GvHD). However, additional studies are needed to deter-
mine the inﬂuence of iron overload on long-term morbidity
and mortality in allogeneic HCT survivors [14].
Inpatientswithacutemyeloid leukemia(AML)receiving
HCT, both inherited and treatment-related factors might
inﬂuence hepcidin expression. Whether hepcidin synthesis
and regulation remain intact despite intensive AML-chem-
otherapy and HCT is yet unknown. Therefore, the impact of
pretransplant body iron load, bloodtransfusions, HFE geno-
type as well as chemotherapy, conditioning regimen, and
graft-versus-host disease (GVHD) on serum hepcidin levels
was analyzed in patients with AML prior to and after allo-
geneic HCT.
2.Materialsand Methods
2.1. Study Design. Between February 2008 and February
2009, 42 consecutive patients with AML in complete remis-
sion who received allogeneic HCT at the University of
Leipzig, Germany, and survived three months were included.
Allpatientswere assessed clinicallyandbiochemically ontwo
occasions: ten days prior to and at a median of 3 (range 3–
5) months after allogeneic HCT. All medications including
antibiotics, antifungal, and immunosuppressive drugs were
recorded. The study was conducted in accordance with the
Declaration of Helsinki [15]. Patients gave written informed
consent.
2.2. Patients. Median age was 57 (range 18–70) years. 23
(54.8%) were male, and 19 (45.2%) patients were female.
Median number of AML-chemotherapies prior to HCT was
3 (range,0–5).Conventional conditioningwith 12Gray total
body irradiation (TBI) and cyclophosphamide 120mg/kg
was given to 13 (31%) patients while 29 (69%) of patients
received HCT following reduced intensity conditioning
(RIC) with ﬂudarabin 30mg/m2/day for 3 days and 2 Gray
TBI applied once followed by immunosuppression with
cyclosporine (through level >200ng/mL) and mycopheno-
latemofetil.Donorswere matchedrelated(MRD)in8(19%)
and matched unrelated (MUD) in 34 (81%) patients. Acute
GVHD conﬁrmed by biopsy of at least one involved site
was graded according to the Glucksberg-Seattle criteria [16].
14 (33.3%) patients developed grade > II acute GVHD of
Table 1: Patient characteristics at baseline (n = 42).
Parameters Results
Mean age, years (range) 57 (18–70)
Gender, n (%)
Male 23 (54.8)
Female 19 (45.2)
Donor, n (%)
MRD 8 (19%)
MUD 34 (81%)
Conditioning, n (%)
Conventional 13 (31.0)
RIC 29 (69.0)
Acute GVHD, n (%)
Skin
No 7 (16.7)
Yes 35 (83.3)
Grade I 21
Grade II 10
Grade III 4
Liver
No 35 (83.3)
Yes 7 (16.7)
Grade I 6
Grade II 1
Grade III 0
Median number of blood transfusions (range)
Prior to HCT 22 (8– 95)
After HCT 30 (14–120)
Median serum ferritin (range) ng/mL
Prior to HCT 1945 (617–6981)
After HCT 2260 (807–7595)
Median serum hepcidin (range) ng/mL
Prior to HCT 358 (56–1096 )
After HCT 398 (172–941)
MRD: matched related donor; MUD: matched unrelated donor; RIC:
reduced intensity conditioning; GVHD: graft versus host disease; HCT:
hematopoietic stem cell transplantation.
the skin while 7 (16.7%) patients suﬀered grade > II acute
GVHD of the liver.
Patients received a median of 22 (range 8–95) units of
blood pre-HCTand a median totalof 30(14–120)unitsafter
HCT. Table 1 summarises patient characteristics.
2.3.BodyIron. Forassessment ofbodyironstores, serumfer-
ritin was measured. At the time of assessment, patients were
in a stable clinical condition without signs of infection and
a concomitant C-reactive protein (CRP) <10mg/L. Normal
reference value for ferritin was 30–400ng/mL.
2.4. Hepcidin. Concomitant with the measurement ofserum
ferritin, serum hepcidin was measured by a hepcidin com-
petitive enzyme-linked immunoassay (C-ELISA) at Intrinsic
LifeSciences LLC, La Jolla, CA, USA, as previously describedAdvances in Hematology 3
[17]. In healthy volunteers, the 5% to 95% range of hepcidin
concentrations was 29–254ng/mL for males (n = 65)
and 17–286ng/mL for females (n = 49) with median
concentrations of 112 and 65ng/mL, respectively (P<. 001)
[17].
In this study, serum hepcidin concentrations of 21
healthy volunteers matched for age and gender (6 male, 15
female, median age 57 years) were used as controls.
2.5. HFE Gene Analysis. Patients were screened for their
HFE genotype prior to and after HCT. Mutations in DNA
extractedfromperipheralbloodweredetectedbypolymerase
chainreaction(PCR)usinghybridizationprobesandmelting
c u r v ea n a l y s i sa sd e s c r i b e dp r e v i o u s l y[ 18].
2.6. DonorCell Chimerism. After conventionalconditioning,
donor chimerism was analysed in unsorted bone marrow
cells day 28 after HCT. For all patients who received RIC
HCT, additionally ﬂow-sorted T (CD3+)-,and CD34+-bone
marrow cells at days 28, 56, 84, and at 3 months interval
thereafter was monitored by ﬂuorescence in situ hybridisa-
tion (FISH) for the XY chromosome in gender mismatched
or PCR-based analysis of polymorphic microsatellite regions
in gender-matched HCT. All patients expressed a full donor
chimerism after HCT.
2.7. Liver and Renal Function. Alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phos-
phates (AP), and bilirubin were evaluated regularly. Normal
laboratory reference value for ALT/AST, AP, and biliru-
bin were ≤0.6mmoL/L, <1.74μkat/L, and <17μmoL/L,
respectively. Creatinine was used to monitor renal function.
Normal reference value for creatinine was <104μmoL/L
(Table 1).
2.8. Statistical Analysis. For statistical analysis Wilcoxon
signed-rank test and Mann-Whitney U test were used. Cox-
Regression was used for multivariate analysis. For nonpara-
metric correlations, we used the Spearman-Rho-Test and
the Pearson-correlation. Data were analyzed using SPSS15
software. A P value of <.05 was considered statistically
signiﬁcant.
3.Results
3.1. Body Iron Stores prior to and after HCT. Prior to allo-
geneic HCT, excess body iron was present in all patients
with a median serum ferritin of 1945 (range 617–6981)
ng/mL.Patientsreceivedamedianof22(range8–95)unitsof
blood. After HCT, the median serum ferritin of 2260 (range
807–7595)ng/mL was not statistically higher than the pre-
transplant level although the number of blood transfusions
after HCT reached a median of 30 (range 14–120) units
which was signiﬁcantly more than that received prior to
HCT (P<. 0005). The number of blood transfusions prior
to HCT strongly correlated with the pretransplant serum
ferritin (P = .001). Again, the posttransplant serum ferritin
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Figure 1:Hepcidin concentrationsin controls andin AML patients
before and after allogeneic HCT (n = 42); ∗P<. 0001, each versus
controls.
was strongly dependent on the cumulative number of blood
units transfused (P<. 001).
3.2. HFE Genotypes prior to and after HCT. Data on HFE
gene status were available in 41 patients prior to and in
40 patients after HCT. In the pre-transplantation setting,
mutations were found in 19 (46.0%) patients. The most
frequently occurring HFE mutation was heterozygosity (het)
for H63D (n = 11), followed by het C282Y (n = 3), and het
S65C(n = 1).Homozygosity (homo)for H63Dwas detected
in 4 patients. After HCT, HFE mutations were detected in 15
(37.5%) patients. Again heterozygosity for H63D occurred
most frequently (n = 12), followed by het S65C (n = 2),
and het C282Y (n = 1). Compound-het was detected in one
patient after allogeneic HCT. Interestingly, in 18 patients the
HFE genotype changed after HCT (Table 2). HFE genotype
at any time point had no inﬂuence on serum ferritin.
3.3. Hemoglobin (Hb) prior to and after HCT. Prior to HCT,
Hb with a median of 10.3 (range 6.8–14.5)g/dL was similar
to Hb levels after HCT (median 10.1 (range 6.7–13.4)g/dL).
There was a negative correlation between Hb levels and
serum ferritin prior to HCT (P = .002). Similarly, higher
ferritin values were associated with lower Hb levels after
transplantation (P = .01).
3.4. Hepcidin Levels prior to and after HCT. The median
hepcidin concentration of 52.1 (range 8.3–130.8)ng/mL in
the 21 healthy volunteers in this analysis was comparable to
thepublishedvaluesinhealthyvolunteersmeasuredwiththis
assay [17].
Patients with AML demonstrated highly elevated serum
hepcidin levels both in the pre-transplant (median 358
(range 56–1096)ng/mL) and post-transplant setting (me-
dian 398 (range 172–941)ng/mL) compared to the control
group (P<. 0001). There was no statistically signiﬁcant4 Advances in Hematology
Table 2: HFE mutations before and after allogeneic HCT.
Patient ID HFE mutations
before HCT
HFE mutations
after HCT
1 heth63D wt
2 homoH63D wt
3w t w t
4w t w t
5 wt heth63D
6w t w t
7w t w t
8w t w t
9 wt heth63D
10 wt wt
11 hetC282Y wt
12 wt wt
13 heth63D −1
14 wt wt
15 hetC282Y wt
16 wt wt
17 wt wt
18 hetH63D hetH63D
19 wt wt
20 hetH63D wt
21 hetC282Y wt
22 hetH63D hetH63D
23 wt hetH63D
24 hetH63D hetH63D
25 hetH63D hetH63D
26 hetH63D hetH63D
27 wt wt
28 wt wt
29 hetH63D hetS65C
30 homoH63D wt
31 homoH63D wt
32 hetS65C wt
33 wt hetH63D
34 wt hetH63D
35 homoH63D wt
36 hetH63D hetS65C
37 hetH63D hetH63D
38 wt comp. het
39 wt wt
40 wt wt
41 wt hetH63D
42 −1 −1
HFE: hereditary hemochromatosis gene; HCT: hematopoietic cell trans-
plantation; het: heterozygous; homo: homozygous; comp. het: compound
heterozygous; wt: wildtype.
diﬀerence between median hepcidin levels prior to and after
HCT (P = .4) (Figure 1).
3.4.1. Correlation of Hepcidin Levels with Blood Transfusions.
Hepcidin levels before HCT strongly correlated with the
number of blood transfusions prior to HCT (P = .001)
(Figure 2(a)). Similarly, post-transplant hepcidin values sig-
niﬁcantly correlated with both the number of blood units
transfused prior to transplantation (P = .008) and the total
units of blood transfused (P<. 001).
3.4.2. Correlation of Hepcidin Levels with Body Iron. Sur-
prisingly in the pre-transplant setting, and although the
number of blood units transfused strongly correlated with
the serum ferritin, no statistical correlation was found
between serum ferritin values prior to HCT and serum
hepcidin concentrations prior to or after transplantation
(Figure 2(b)).
3.4.3. Correlation of Serum Hepcidin with Hb Levels. Hep-
cidin concentrations signiﬁcantly correlated inversely with
Hb values (P = .002) (Figure 2(c)). A similar association
could be found between hepcidin and Hb values after HCT
(P = .001).
3.4.4. Eﬀect of HFE Genotype on Hepcidin Levels. In our
cohort, HFE genotype prior to or after HCT had no impact
on hepcidin values at any time point.
3.4.5. Eﬀect of Other Patient Characteristics on Hepcidin Lev-
els. In univariate analysis, age and gender had no signiﬁcant
inﬂuence on hepcidin values before or after HCT. Similarly,
liver and renal functions, number of prior chemotherapies,
andtypeofconditioningregimenhadnoimpactonhepcidin
levels either before or after HCT.
3.5. Outcome after HCT. After a median followup of 21
(range 17–28) months, the probability of survival and
leukemia-free survival (LFS) at 2 years were 66% and
64%, respectively. The incidences of relapse and nonrelapse
mortality (NRM) at 2 years were 20%. In this analysis,
pre- and post-HCT serum ferritin and hepcidin levels as
well as the number of blood transfusions did not correlate
with survival, LFS, relapse, or NRM. Acute graft-versus-
host disease (GVHD) which occurred in 35 (83%) patients
was limited to acute cutaneous GVHD stage I and II in
31 patients. Chronic GVHD (limited, n = 4, extensive,
n = 18) was present in 22 (53%) patients. Again, there
was no association between the occurrence and the severity
of GVHD on one side and pre- or post-HCT body iron
or hepcidin levels on the other side. In the ﬁrst 100 days
post-HCT, 12 (29%) patients suﬀered a nonlethal grade 3
infection according to common toxicitycriteria. In the entire
cohort, serum ferritin or hepcidin values did not inﬂuence
t h eo c c u r r e n c eo fs e v e r ei n f e c t i o n s .
4.Discussion
Evidence for iron overload as determined by serum fer-
ritin concentrations was found in all polytransfused AML
patients. Serum ferritin is a practical measure of body ironAdvances in Hematology 5
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Figure 2: Correlation of serum hepcidin levels with number of blood transfusions (a), serum ferritin values (b), and hemoglobin levels (c)
before HCT.
that can easily be applied and is supposed to represent a
reliable marker ofbody iron stores [19–21].Althoughfactors
such as infection, acute and chronic inﬂammation, and
alcohol abuse can exert an inﬂuence on individual values,
both the stable clinical condition and the concomitant low
CRP in all patients suggest that the serum ferritin mainly
reﬂected body iron stores.
It is not surprising that serum ferritin at all time points
strongly correlated with the number of blood transfusions as
ironoverload,commonlyobservedinrecipientsofallogeneic
HCT, is mainly attributed to multiple blood transfusions.
But other factors as overexpression of the growth and dif-
ferentiation factor (GDF-15) which inhibits the production
of hepcidin in the liver have been discussed as possible
contributors to excess body iron in thalassemia [22].
In this study, patients with AML compared to healthy
volunteers demonstrated highly elevated serum hepcidin
levels strongly correlating with the number of blood trans-
fusions both in the pre- and post-transplant setting. This
ﬁnding suggests that transfusional iron remains a dominant
regulator of hepcidin in these patients and that hepcidin
synthesis and regulation remain intact in polytransfused
patients with AML undergoing allogeneic HCT irrespective
of the number of prior chemotherapies, type ofconditioning
regimen, or antifungal treatments.
Usually, hepcidin and serum ferritin respond similarly to
inﬂammation and changes in iron stores, and this is reﬂected
in the strong correlation between hepcidin and ferritin in
healthy volunteers with hepcidin responses taking place on
thetimescaleofafew hours,whereas changesinferritin con-
centrations are much slower [23].However,no correlationof
pre- or post-HCT hepcidin levels with serum ferritin values
prior to HCT was found despite the fact that both serum
ferritin and hepcidin were strongly aﬀected by the number
of blood units transfused. Also, pre- and post-transplant
serum ferritin and hepcidin values were statistically similar
despite signiﬁcantly higher cumulative blood units received
after HCT. These data suggest that hepcidin represents
a compensatory mechanism that counteracts transfusional
iron input.Hepcidinisknown tobindtoferroportin, leading
to intracellular retention of iron in macrophages and to a
reductionofextracellular ironbound totransferrin orserum
ferritin [24]. This raises the fascinating question of whether
elevated hepcidin values in the presence of transfusional
iron loading might protect from excessive parenchymal iron
overload and subsequent organ damage.6 Advances in Hematology
An elevated hepcidin expression as a proposed cause of
anemia of chronic inﬂammation [7] might explain the
inverse correlation of hepcidin levels with Hb values ob-
served in this study and highlight the complexity of hepcidin
regulation.
As HFE genemutations have a high frequency in popula-
tion of European descent [9–11], patients in this study were
screened prior to and after HCT for HFE gene mutations
to determine whether HFE genotype contributed to excess
iron and to assess the impact of HFE gene mutations on
hepcidin concentrations. As all patients after HCT expressed
full donor chimerism, the HFE genotype after HCT must
be considered to reﬂect donor genotype. HFE deletions or
mutations have been associated with a reduction of liver
hepcidin expression [12, 25–27]. However, it is presently
controversial whether HFE is indispensable for hepcidin
activation in response to inﬂammatory stimuli [28–30].
Mutations of HFE account for most but not all cases
of hemochromatosis [31]. The most common mutation,
C282Y, is associated with disruption of a disulﬁde bond in
H F Et h a ti sc r i t i c a lf o ri t sb i n d i n gt oβ2 microglobulin [32].
This interaction is required for the stabilisation, transport,
and expression of HFE on the cell surface and endosomal
membranes where HFE interacts with the transferrin recep-
tor1 (TfR1).The H63Dmutation,acommonHFEmutation
whose pathogenic signiﬁcance is still uncertain, does not
impairinteractionbetweenHFEandTfR1.AstheH63DHFE
mutation was the only mutation commonly detected in our
cohort, this might in part explain why HFE genotype had no
inﬂuence on serum hepcidin levels.
Similarly, the missing association between HFE genotype
and serum ferritin in our cohort is in accordance with
published data. Veneri et al. studied the prevalence of 12
mutations of the HFE gene and its correlation with the iron
status in 82 adult patients with acute leukemia of whom
58.5% were aﬀected by acute myeloid leukemia (AML) [33].
32.9% of the patients had at least one HFE gene mutation
and mean serum ferritin levels were increased at diagnosis.
However, there was no diﬀerence between patients positive
or negative for the HFE mutations in terms of serum ferritin
levels. The study therefore highlighted the presence of iron
overload in many AML patients but did not support the
evidence of an association between HFE mutations and iron
overload in acute leukemia [33].
Increased pre-transplant iron overload has been demon-
strated to represent negative prognostic factors in patients
with myelodysplastic syndromes or secondary AML [34],
thalassemia, and other hematologic disorders such as acute
leukemias [35, 36] receiving HCT irrespective of the type of
conditioning [35–37].
The impact of an elevated hepcidin level on outcome
after HCT is not yet known. But few data suggest that pre-
transplant serum hepcidin levels might predict the risk of
early infectious bacterial complications after allogeneic HCT
[38].
Although the aim of this work was not to study the
impact of hepcidin values on outcome after HCT, neverthe-
less no negative impact of an elevated pre-transplant hep-
cidin concentration on outcome, the incidence or severity of
acute or chronic GVHD, or early infectious complications
after HCT could be detected in this cohort. It is important
to keep in mind that this was a small series of patients
surviving the ﬁrst three months after HCT. Nevertheless,
this observation merits further investigation with a higher
number of patients.
5.Conclusions
Fortheﬁrst time,wedescribehighlyelevatedserumhepcidin
concentrations in AML patients with transfusional iron load
b o t hp r i o rt oa n da f t e rH C Tu s i n gt h eC - E L I S Af o rh u m a n
serum hepcidin assessment. This suggests that hepcidin
synthesis and upregulation remain intact despite intensive
chemotherapy and HCT. The weak correlation between pre-
transplant serum ferritin and both pre- or post-transplant
serum hepcidin is highly interesting although both pre-
and post-transplant levels of serum ferritin and hepcidin
were similar and correlated, as would be expected, with
the number of blood units received. So Overexpression
of hepcidin might represent a compensatory mechanism
counteracting transfusional iron input.
Actually, overexpression of hepcidin might play an im-
portant protective role in this setting as it might prevent
an increased ferroportin-mediated iron export from macro-
phages thereby reducing the severity of parenchymal iron
loading and damage. In contrast to ferritin, a marker of iron
stores, changes in hepcidin concentrations are frequently the
cause of iron disorders. Thus, measurements of hepcidin
concentrations in addition to serum ferritin might be highly
informative in understanding iron homeostasis in the setting
of HCT. To establish the exact impact of serum hepcidin on
outcome after HCT, large prospective studies are warranted.
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